Berge Viktor, Thompson Trevor, Blackman Donald
Urological Department, Akershus University Hospital, Nordbyhagen, Norway.
Scand J Urol Nephrol. 2007;41(3):198-203. doi: 10.1080/00365590601016677.
To examine how the use of additional treatment for prostate cancer differs as a function of the initial therapy (radical prostatectomy [RP], radiation therapy [RT], androgen deprivation therapy [ADT], or watchful waiting [WW]) for men with non-metastatic prostate cancer.
A dataset was created that combined information from the Surveillance, Epidemiology, and End Results program and Medicare claims for hospital and physician services. To identify patients receiving additional cancer treatment, we searched the claims for the presence of RP, RT (palliative radiation not included), or ADT.
The study population consisted of 12 711 patients: as initial treatment, 3940 (31.0%) had RP, 3950 (31.1%) RT, 1209 (9.5%) ADT, and 3612 (28.4%) WW. The RP group had a less favorable distribution of tumor differentiation than the RT group. Only 54.6% of men who had initial RP had localized cancer. In men who had initial RP, 8.1% had RT and 12.4% ADT during the follow-up period, which was 6-66 months after the initial therapy ended. Among patients who had initial RT or WW, 22.8% and 22.1%, respectively had ADT during the follow-up period.
Older American men with prostate cancer who are initially treated with RT or simply observed (WW) are more likely than men who undergo RP to receive ADT as a follow-up treatment.
研究对于非转移性前列腺癌男性患者，前列腺癌额外治疗的使用情况如何因初始治疗（根治性前列腺切除术[RP]、放射治疗[RT]、雄激素剥夺治疗[ADT]或观察等待[WW]）的不同而有所差异。
创建了一个数据集，该数据集整合了监测、流行病学和最终结果计划以及医疗保险关于医院和医生服务索赔的信息。为了识别接受额外癌症治疗的患者，我们在索赔记录中搜索RP、RT（不包括姑息性放疗）或ADT的记录。
研究人群包括12711名患者：作为初始治疗，3940名（31.0%）接受了RP，3950名（31.1%）接受了RT，1209名（9.5%）接受了ADT，3612名（28.4%）接受了WW。RP组的肿瘤分化分布情况不如RT组。初始接受RP的男性中只有54.6%患有局限性癌症。在初始接受RP的男性中，8.1%在随访期间接受了RT，12.4%接受了ADT，随访期为初始治疗结束后的6至66个月。在初始接受RT或WW的患者中，分别有22.8%和22.1%在随访期间接受了ADT。
与接受RP治疗的男性相比，最初接受RT治疗或仅进行观察（WW）的美国老年前列腺癌男性患者作为后续治疗接受ADT的可能性更大。
